Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Liver Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Liver Diseases 1Hepatitis 1Gastrointestinal Neoplasms 1Fibrosis 1

Interventions

Sorafenib 5lenvatinib 3sintilimab 2pembrolizumab 2halofantrine 2camrelizumab 2atezolizumab 2Immunotherapy 2Blood Specimen Collection 2Bevacizumab 2Antibodies 2trifluridine tipiracil drug combination 1trametinib 1toripalimab 1titanium silicide 1tislelizumab 1linifanib 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1fisogatinib 1ficlatuzumab 1durvalumab 1bavituximab 1avelumab 1User-Centered Design 1Sunitinib 1Sufentanil 1Standard of Care 1Shadowing Technique, Histology 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Diseases × bavituximab × Gastrointestinal × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡